Home
Insight: Evidence grows for narcolepsy link to GSK swine flu shot
By Kate Kelland, Health and Science Correspondent, Reuters
Jan. 22, 2013 12:03AM PSTJan. 22, 2013 12:03AM PST
Emelie Olsson falls asleep as he watches television in her apartment in Stockholm, January 17, 2013. Emelie is one of around 800 children in Sweden and elsewhere in Europe who developed narcolepsy, an incurable sleep disorder, after being immunised in 2009 with the Pandemrix H1N1 swine flu vaccine made by British drugmaker GlaxoSmithKline. Picture taken January 17, 2013. REUTERS/Ints Kalnins
STOCKHOLM (Reuters) - Emelie is plagued by hallucinations and nightmares. When she wakes up, she's often paralyzed, unable to breathe properly or call for help. During the day she can barely stay awake, and often misses school or having fun with friends. She is only 14, but at times she has wondered if her life is worth living.
Emelie is one of around 800 children in Sweden and elsewhere in Europe who developed narcolepsy, an incurable sleep disorder, after being immunized with the Pandemrix H1N1 swine flu vaccine made by British drugmaker GlaxoSmithKline in 2009.
Finland, Norway, Ireland and France have seen spikes in narcolepsy cases, too, and people familiar with the results of a soon-to-be-published study in Britain have told Reuters it will show a similar pattern in children there.
Their fate, coping with an illness that all but destroys normal life, is developing into what the health official who coordinated Sweden's vaccination campaign calls a "medical tragedy" that will demand rising scientific and medical attention.
Europe's drugs regulator has ruled Pandemrix should no longer be used in people aged under 20. The chief medical officer at GSK's vaccines division, Norman Begg, says his firm views the issue extremely seriously and is "absolutely committed to getting to the bottom of this", but adds there is not yet enough data or evidence to suggest a causal link.
Others - including Emmanuel Mignot, one of the world's leading experts on narcolepsy, who is being funded by GSK to investigate further - agree more research is needed but say the evidence is already clearly pointing in one direction.
"There's no doubt in my mind whatsoever that Pandemrix increased the occurrence of narcolepsy onset in children in some countries - and probably in most countries," says Mignot, a specialist in the sleep disorder at Stanford University in the United States.
30 MILLION RECEIVED PANDEMRIX
In total, the GSK shot was given to more than 30 million people in 47 countries during the 2009-2010 H1N1 swine flu pandemic. Because it contains an adjuvant, or booster, it was not used in the United States because drug regulators there are wary of adjuvanted vaccines.
GSK says 795 people across Europe have reported developing narcolepsy since the vaccine's use began in 2009.
Questions about how the narcolepsy cases are linked to Pandemrix, what the triggers and biological mechanisms might have been, and whether there might be a genetic susceptibility are currently the subject of deep scientific investigation.
But experts on all sides are wary. Rare adverse reactions can swiftly develop into "vaccine scares" that spiral out of proportion and cast what one of Europe's top flu experts calls a "long shadow" over public confidence in vaccines that control potential killers like measles and polio.
"No-one wants to be the next Wakefield," said Mignot, referring to the now discredited British doctor Andrew Wakefield who sparked a decades-long backlash against the measles, mumps and rubella (MMR) shot with false claims of links to autism.
With the narcolepsy studies, there is no suggestion that the findings are the work of one rogue doctor.
Independent teams of scientists have published peer-reviewed studies from Sweden, Finland and Ireland showing the risk of developing narcolepsy after the 2009-2010 immunization campaign was between seven and 13 times higher for children who had Pandemrix than for their unvaccinated peers.
"We really do want to get to the bottom of this. It's not in anyone's interests if there is a safety issue that needs to be addressed," said GSK's Begg.
LIFE CHANGED
Emelie's parents, Charles and Marie Olsson, say she was a top student who loved playing the piano, taking tennis lessons, creating art and having fun with friends. But her life started to change in early 2010, a few months after she had Pandemrix. In the spring of 2010, they noticed she was often tired, needing to sleep when she came home from school.
But it wasn't until May, when she began collapsing at school, that it became clear something serious was happening.
As well as the life-limiting bouts of daytime sleepiness, narcolepsy brings nightmares, hallucinations, sleep paralysis and episodes of cataplexy - when strong emotions trigger a sudden and dramatic loss of muscle strength.
In Emelie's case, having fun is the emotional trigger. "I can't laugh or joke about with my friends anymore, because when I do I get cataplexies and collapse," she said in an interview at her home in the Swedish capital.
Narcolepsy is estimated to affect between 200 and 500 people per million and is a lifelong condition. It has no known cure and scientists don't really know what causes it. But they do know patients have a deficit of a brain neurotransmitter called orexin, also known as hypocretin, which regulates wakefulness.
Research has found that some people are born with a variant in a gene known as HLA that means they have low hypocretin, making them more susceptible to narcolepsy. Around 25 percent of Europeans are thought to have this genetic vulnerability.
When results of Emelie's hypocretin test came back in November last year, it showed she had 15 percent of the normal amount, typical of heavy narcolepsy with cataplexy.
The seriousness of her strange new illness has forced her to contemplate life far more than many other young teens: "In the beginning I didn't really want to live any more, but now I have learned to handle things better," she said.
TRIGGERS?
Scientists investigating these cases are looking in detail at Pandemrix's adjuvant, called AS03, for clues.
Some suggest AS03, or maybe its boosting effect, or even the H1N1 flu itself, may have triggered the onset of narcolepsy in those who have the susceptible HLA gene variant.
Angus Nicoll, a flu expert at the European Centre for Disease Prevention and Control (ECDC), says genes may well play a part, but don't tell the whole story.
"Yes, there's a genetic predisposition to this condition, but that alone cannot explain these cases," he said. "There was also something to do with receiving this specific vaccination. Whether it was the vaccine plus the genetic disposition alone or a third factor as well - like another infection - we simply do not know yet."
GSK is funding a study in Canada, where its adjuvanted vaccine Arepanrix, similar to Pandemrix, was used during the 2009-2010 pandemic. The study won't be completed until 2014, and some experts fear it may not shed much light since the vaccines were similar but not precisely the same.
It all leaves this investigation with far more questions than answers, and a lot more research ahead.
WAS IT WORTH IT?
In his glass-topped office building overlooking the Maria Magdalena church in Stockholm, Goran Stiernstedt, a doctor turned public health official, has spent many difficult hours going over what happened in his country during the swine flu pandemic, wondering if things should have been different.
"The big question is was it worth it? And retrospectively I have to say it was not," he told Reuters in an interview.
Being a wealthy country, Sweden was at the front of the queue for pandemic vaccines. It got Pandemrix from GSK almost as soon as it was available, and a nationwide campaign got uptake of the vaccine to 59 percent, meaning around 5 million people got the shot.
Stiernstedt, director for health and social care at the Swedish Association of Local Authorities and Regions, helped coordinate the vaccination campaign across Sweden's 21 regions.
The World Health Organization (WHO) says the 2009-2010 pandemic killed 18,500 people, although a study last year said that total might be up to 15 times higher.
While estimates vary, Stiernstedt says Sweden's mass vaccination saved between 30 and 60 people from swine flu death. Yet since the pandemic ended, more than 200 cases of narcolepsy have been reported in Sweden.
With hindsight, this risk-benefit balance is unacceptable. "This is a medical tragedy," he said. "Hundreds of young people have had their lives almost destroyed."
PANDEMICS ARE EMERGENCIES
Yet the problem with risk-benefit analyses is that they often look radically different when the world is facing a pandemic with the potential to wipe out millions than they do when it has emerged relatively unscathed from one, like H1N1, which turned out to be much milder than first feared.
David Salisbury, the British government's director of immunization, says "therein lies the risk, and the difficulty, of working in public health" when a viral emergency hits.
"In the event of a severe pandemic, the risk of death is far higher than the risk of narcolepsy," he told Reuters. "If we spent longer developing and testing the vaccine on very large numbers of people and waited to see whether any of them developed narcolepsy, much of the population might be dead."
Pandemrix was authorized by European drug regulators using a so-called "mock-up procedure" that allows a vaccine to be authorized ahead of a possible pandemic using another flu strain. In Pandemrix's case, the substitute was H5N1 bird flu.
When the WHO declared a pandemic, GSK replaced the mock-up's strain with the pandemic-causing H1N1 strain to form Pandemrix.
GSK says the final H1N1 version was tested in trials involving around 3,600 patients, including children, adolescents, adults and the elderly, before it was rolled out.
The ECDC's Nicoll says early warning systems that give a more accurate analysis of a flu strain's threat are the best way to minimize risks of this kind of tragedy happening in future.
Salisbury agrees, and says progress towards a universal flu vaccine - one that wouldn't need last-minute changes made when a new strain emerged - would cuts risks further.
"Ideally, we would have a better vaccine that would work against all strains of influenza and we wouldn't need to worry about this ever again," he said. "But that's a long way off."
With scientists facing years of investigation and research, Emelie just wants to make the best of her life.
She reluctantly accepts that to do so, she needs a cocktail of drugs to try to control the narcolepsy symptoms. The stimulant Ritalin and the sleeping pill Sobril are prescribed for Emelie's daytime sleepiness and night terrors. Then there's Prozac to try to stabilize her and limit her cataplexies.
"That's one of the things that makes me feel most uncomfortable," she explains. "Before I got this condition I didn't take any pills, and now I have to take lots - maybe for the rest of my life. It's not good to take so many medicines, especially when you know they have side effects."
(Reporting by Kate Kelland; Editing by Will Waterman)
http://health.yahoo.net/news/s/nm/insight-evidence-grows-for-narcolepsy-link-to-gsk-swine-flu-shot
By Kate Kelland, Health and Science Correspondent, Reuters
Jan. 22, 2013 12:03AM PSTJan. 22, 2013 12:03AM PST
Emelie Olsson falls asleep as he watches television in her apartment in Stockholm, January 17, 2013. Emelie is one of around 800 children in Sweden and elsewhere in Europe who developed narcolepsy, an incurable sleep disorder, after being immunised in 2009 with the Pandemrix H1N1 swine flu vaccine made by British drugmaker GlaxoSmithKline. Picture taken January 17, 2013. REUTERS/Ints Kalnins
STOCKHOLM (Reuters) - Emelie is plagued by hallucinations and nightmares. When she wakes up, she's often paralyzed, unable to breathe properly or call for help. During the day she can barely stay awake, and often misses school or having fun with friends. She is only 14, but at times she has wondered if her life is worth living.
Emelie is one of around 800 children in Sweden and elsewhere in Europe who developed narcolepsy, an incurable sleep disorder, after being immunized with the Pandemrix H1N1 swine flu vaccine made by British drugmaker GlaxoSmithKline in 2009.
Finland, Norway, Ireland and France have seen spikes in narcolepsy cases, too, and people familiar with the results of a soon-to-be-published study in Britain have told Reuters it will show a similar pattern in children there.
Their fate, coping with an illness that all but destroys normal life, is developing into what the health official who coordinated Sweden's vaccination campaign calls a "medical tragedy" that will demand rising scientific and medical attention.
Europe's drugs regulator has ruled Pandemrix should no longer be used in people aged under 20. The chief medical officer at GSK's vaccines division, Norman Begg, says his firm views the issue extremely seriously and is "absolutely committed to getting to the bottom of this", but adds there is not yet enough data or evidence to suggest a causal link.
Others - including Emmanuel Mignot, one of the world's leading experts on narcolepsy, who is being funded by GSK to investigate further - agree more research is needed but say the evidence is already clearly pointing in one direction.
"There's no doubt in my mind whatsoever that Pandemrix increased the occurrence of narcolepsy onset in children in some countries - and probably in most countries," says Mignot, a specialist in the sleep disorder at Stanford University in the United States.
30 MILLION RECEIVED PANDEMRIX
In total, the GSK shot was given to more than 30 million people in 47 countries during the 2009-2010 H1N1 swine flu pandemic. Because it contains an adjuvant, or booster, it was not used in the United States because drug regulators there are wary of adjuvanted vaccines.
GSK says 795 people across Europe have reported developing narcolepsy since the vaccine's use began in 2009.
Questions about how the narcolepsy cases are linked to Pandemrix, what the triggers and biological mechanisms might have been, and whether there might be a genetic susceptibility are currently the subject of deep scientific investigation.
But experts on all sides are wary. Rare adverse reactions can swiftly develop into "vaccine scares" that spiral out of proportion and cast what one of Europe's top flu experts calls a "long shadow" over public confidence in vaccines that control potential killers like measles and polio.
"No-one wants to be the next Wakefield," said Mignot, referring to the now discredited British doctor Andrew Wakefield who sparked a decades-long backlash against the measles, mumps and rubella (MMR) shot with false claims of links to autism.
With the narcolepsy studies, there is no suggestion that the findings are the work of one rogue doctor.
Independent teams of scientists have published peer-reviewed studies from Sweden, Finland and Ireland showing the risk of developing narcolepsy after the 2009-2010 immunization campaign was between seven and 13 times higher for children who had Pandemrix than for their unvaccinated peers.
"We really do want to get to the bottom of this. It's not in anyone's interests if there is a safety issue that needs to be addressed," said GSK's Begg.
LIFE CHANGED
Emelie's parents, Charles and Marie Olsson, say she was a top student who loved playing the piano, taking tennis lessons, creating art and having fun with friends. But her life started to change in early 2010, a few months after she had Pandemrix. In the spring of 2010, they noticed she was often tired, needing to sleep when she came home from school.
But it wasn't until May, when she began collapsing at school, that it became clear something serious was happening.
As well as the life-limiting bouts of daytime sleepiness, narcolepsy brings nightmares, hallucinations, sleep paralysis and episodes of cataplexy - when strong emotions trigger a sudden and dramatic loss of muscle strength.
In Emelie's case, having fun is the emotional trigger. "I can't laugh or joke about with my friends anymore, because when I do I get cataplexies and collapse," she said in an interview at her home in the Swedish capital.
Narcolepsy is estimated to affect between 200 and 500 people per million and is a lifelong condition. It has no known cure and scientists don't really know what causes it. But they do know patients have a deficit of a brain neurotransmitter called orexin, also known as hypocretin, which regulates wakefulness.
Research has found that some people are born with a variant in a gene known as HLA that means they have low hypocretin, making them more susceptible to narcolepsy. Around 25 percent of Europeans are thought to have this genetic vulnerability.
When results of Emelie's hypocretin test came back in November last year, it showed she had 15 percent of the normal amount, typical of heavy narcolepsy with cataplexy.
The seriousness of her strange new illness has forced her to contemplate life far more than many other young teens: "In the beginning I didn't really want to live any more, but now I have learned to handle things better," she said.
TRIGGERS?
Scientists investigating these cases are looking in detail at Pandemrix's adjuvant, called AS03, for clues.
Some suggest AS03, or maybe its boosting effect, or even the H1N1 flu itself, may have triggered the onset of narcolepsy in those who have the susceptible HLA gene variant.
Angus Nicoll, a flu expert at the European Centre for Disease Prevention and Control (ECDC), says genes may well play a part, but don't tell the whole story.
"Yes, there's a genetic predisposition to this condition, but that alone cannot explain these cases," he said. "There was also something to do with receiving this specific vaccination. Whether it was the vaccine plus the genetic disposition alone or a third factor as well - like another infection - we simply do not know yet."
GSK is funding a study in Canada, where its adjuvanted vaccine Arepanrix, similar to Pandemrix, was used during the 2009-2010 pandemic. The study won't be completed until 2014, and some experts fear it may not shed much light since the vaccines were similar but not precisely the same.
It all leaves this investigation with far more questions than answers, and a lot more research ahead.
WAS IT WORTH IT?
In his glass-topped office building overlooking the Maria Magdalena church in Stockholm, Goran Stiernstedt, a doctor turned public health official, has spent many difficult hours going over what happened in his country during the swine flu pandemic, wondering if things should have been different.
"The big question is was it worth it? And retrospectively I have to say it was not," he told Reuters in an interview.
Being a wealthy country, Sweden was at the front of the queue for pandemic vaccines. It got Pandemrix from GSK almost as soon as it was available, and a nationwide campaign got uptake of the vaccine to 59 percent, meaning around 5 million people got the shot.
Stiernstedt, director for health and social care at the Swedish Association of Local Authorities and Regions, helped coordinate the vaccination campaign across Sweden's 21 regions.
The World Health Organization (WHO) says the 2009-2010 pandemic killed 18,500 people, although a study last year said that total might be up to 15 times higher.
While estimates vary, Stiernstedt says Sweden's mass vaccination saved between 30 and 60 people from swine flu death. Yet since the pandemic ended, more than 200 cases of narcolepsy have been reported in Sweden.
With hindsight, this risk-benefit balance is unacceptable. "This is a medical tragedy," he said. "Hundreds of young people have had their lives almost destroyed."
PANDEMICS ARE EMERGENCIES
Yet the problem with risk-benefit analyses is that they often look radically different when the world is facing a pandemic with the potential to wipe out millions than they do when it has emerged relatively unscathed from one, like H1N1, which turned out to be much milder than first feared.
David Salisbury, the British government's director of immunization, says "therein lies the risk, and the difficulty, of working in public health" when a viral emergency hits.
"In the event of a severe pandemic, the risk of death is far higher than the risk of narcolepsy," he told Reuters. "If we spent longer developing and testing the vaccine on very large numbers of people and waited to see whether any of them developed narcolepsy, much of the population might be dead."
Pandemrix was authorized by European drug regulators using a so-called "mock-up procedure" that allows a vaccine to be authorized ahead of a possible pandemic using another flu strain. In Pandemrix's case, the substitute was H5N1 bird flu.
When the WHO declared a pandemic, GSK replaced the mock-up's strain with the pandemic-causing H1N1 strain to form Pandemrix.
GSK says the final H1N1 version was tested in trials involving around 3,600 patients, including children, adolescents, adults and the elderly, before it was rolled out.
The ECDC's Nicoll says early warning systems that give a more accurate analysis of a flu strain's threat are the best way to minimize risks of this kind of tragedy happening in future.
Salisbury agrees, and says progress towards a universal flu vaccine - one that wouldn't need last-minute changes made when a new strain emerged - would cuts risks further.
"Ideally, we would have a better vaccine that would work against all strains of influenza and we wouldn't need to worry about this ever again," he said. "But that's a long way off."
With scientists facing years of investigation and research, Emelie just wants to make the best of her life.
She reluctantly accepts that to do so, she needs a cocktail of drugs to try to control the narcolepsy symptoms. The stimulant Ritalin and the sleeping pill Sobril are prescribed for Emelie's daytime sleepiness and night terrors. Then there's Prozac to try to stabilize her and limit her cataplexies.
"That's one of the things that makes me feel most uncomfortable," she explains. "Before I got this condition I didn't take any pills, and now I have to take lots - maybe for the rest of my life. It's not good to take so many medicines, especially when you know they have side effects."
(Reporting by Kate Kelland; Editing by Will Waterman)
http://health.yahoo.net/news/s/nm/insight-evidence-grows-for-narcolepsy-link-to-gsk-swine-flu-shot
» Al-Kazemi opens fire after “silence”: We faced a disaster that the policies of those who accuse us o
» The Iraqi Council of Ministers adopts Al-Kazemi's position regarding the federal decision and issues
» Blackshart informs the Security Council of its concern over desertification and the negative politic
» The Iraqi government decides to increase the purchase price of wheat from farmers to 850 thousand di
» The Iraqi government: Work is underway to restore the Food Security Law through constitutional and l
» Including taxis.. the Iraqi government takes 5 new decisions
» The Council of Ministers agrees to waive the debts owed by the scientific competencies of the displa
» The Central Bank of Iraq postpones the payment of the installments of its initiative loans from the
» The House of Representatives publishes the agenda for Thursday's session
» New guidance for the 100,000 dinars grant
» The Council of Ministers holds its session headed by Al-Kazemi
» Al-Zamili: We will exclude any paragraph of the Food Security Law that can be exploited by wasting p
» The "dilemma" of forming the government continues.. Will the initiative of the independents succeed
» Zidane and the Minister of Security and Justice in the Netherlands discuss common legal issues in th
» Al-Kazemi: We tolerated defamation, lies and fabrication for the sake of our people
» Alsumaria News publishes the agenda of the parliament session next Thursday
» New Cabinet decisions, including the "wheat crop"
» The Secretariat of the Council of Ministers responds to the amendment of the Judicial Fees Law: A ca
» The Central Bank Postpones The Payment Of Loan Installments For Its Initiative From The Agricultural
» The Shortage Of Ration Items Prompts A Parliamentary Bloc To Host The Minister Of Trade
» Al-Rubaie receives the Kuwaiti ambassador and discusses with him the developments of the political s
» Al-Zamili: Food security is on the Parliament table for the next session
» The Minister of Electricity meets the President of the Federal Supreme Court
» Soon.. Baghdad will host a meeting between the foreign ministers of Iran and Saudi Arabia
» The Iraqi parliament sets tomorrow, Wednesday, the first reading of the Food Security Law
» Iraq: Debts and receivables for imported Iranian gas are still pending in many of its details
» What are the alternatives to the political process in Iraq to get out of the quotas? Urgent
» The President Of The Republic Receives The Credentials Of Three New Ambassadors
» Deputy: Al-Kazemi Government's Policies Contributed To The Rise In Poverty Rates
» Deputy: The Canceled Food Security Law Granted The Region Huge Sums Of Money For Free
» Turkmen Warning Against Exceeding Kirkuk Oil
» State Of Law: The Triple Alliance Was Broken Up And Over
» "Al-Hanana" denies, via Shafaq News, that Al-Sadr received a message from the Najaf authority: This
» This is what it has and what it has to do..a legal expert detailing the powers of the Iraqi caretake
» Al-Kazemi’s advisor: The Federal Court’s decision cut off the way for the government’s demand to sub
» Kurdistan Judicial Council: The oil law in the region does not violate the constitution, and its pro
» Parliamentary Finance talks about “constitutional and judicial obstacles” that prevent the enactment
» Parliamentary Economy Chooses A President And Two Deputies
» In preparation for the second reading.. a parliamentary meeting to discuss the “criminalization of n
» The selection of the chairperson and his two deputies to the Electricity, Energy, Transport and Comm
» Water Resources denies statements by the Turkish ambassador in Baghdad,
» The Legal Committee discusses the law criminalizing normalization with the Zionist entity,
» In the presence of the heads of the blocs.. Postponing the meeting of the Kurdistan Parliament Presi
» Oil prices fall as profit taking continues
» Iraqi Oil Minister: We seek to raise the value of energy investments to $17 billion
» India's oil imports rise, Iraq leads exporters
» Al-Rasheed Bank announces facilities for obtaining an advance three times the salary
» Because of import.. Salah El-Din was promoted, complaining of stagnation and low prices
» In pictures.. Barham Salih receives the credentials of the Iranian ambassador and the ambassadors of
» Rule of Law: The issue of dissolving Parliament is an escape from the problem
» A slight increase in the price of the dollar against the Iraqi dinar
» A judge responds to federalism.. the political forces have exceeded the constitutional terms, and Al
» After al-Sadr's speech, the factions talk about "blind sedition" and "severe consequences from which
» The International Finance Corporation praises the efforts of the Kurdistan government to implement r
» International Security holds a session on Iraq
» The coordination framework describes al-Sadr’s speech as “misleading” and calls on him to abandon “p
» Kurdistan refuses to hand over oil and gas to Baghdad
» Waiting for the industrial cities, Ur city and Nasiriyah airport.. 100,000 graduates are waiting for
» The appointment of more than two thousand Iraqi workers in the Karbala refinery
» A government effort to include the Baghdad suspended train in the budget
» Observers: Al-Sadr closed all doors with the coordination framework.. and there are no signs of reso
» A “fiery” speech by Al-Sadr and a statement by “The Frame” .. The secrets of the sharp debate in Ira
» A 'detailed' statement from the framework after al-Sadr's speech
» Finance reports Al-Kazemi with a rise in total foreign currency reserves
» Industry: waste recycling plants attract investors
» Khaled Al-Samarrai was chosen as the head of the age for the Parliamentary Committee on Electricity
» The political scene.. Deputy: The blockage is still there and the situation is the same
» Recruitment order issued against Hoshyar Zebari
» Al-Sudani submits a proposal to cover emergency expenses and support the ration card
» Saleh: We support international and regional cooperation to confront the challenges of terrorism, th
» Choosing the heads of the age for three parliamentary committees
» Oil prices drop, Brent crude records $114 a barrel
» Dollar exchange rates in the Iraqi local markets
» Iraq ranks third in buying Turkish homes
» Al-Rasheed Bank announces the reduction of the minimum requirements for applying for the "Card Card"
» Al-Amiri: The forces that created the mass graves regime are maliciously seeking to revive its bruta
» A parliamentary committee calls for the internationalization of the issue of mass graves and compens
» The coordination framework issues a statement on the latest developments
» A deputy submits a proposal to cover emergency expenses and support the ration card
» The Ministry of Education issues special instructions for the tasks of managing the examination cent
» President of the Republic: We support international and regional cooperation to confront the challen
» The political blockage hinders the formation of the government
» In the document.. the General Secretariat responds to the Ministry of Health regarding the exemption
» Low oil prices
» The stability of the dollar exchange rates in the local markets
» Slight increase in gold prices
» Three parliamentary committees choose their chairs
» Iraq aims to produce 6 million barrels of oil per day by the end of 2027
» Iraq indicates economic and financial recovery: We want more
» Al-Kazemi chairs a meeting to discuss the current financial and economic conditions and confirms the
» Minister of Commerce: The Federal Court's decision put us in front of a new responsibility
» Electricity: Failure to pass the emergency subsidy law will put us at risk of cutting off gas suppli
» After the decision of the Federal Court .. What are the laws that the House of Representatives has t
» Trade clarifies the consequences of canceling the emergency support law on strategic storage and the
» Al-Kazemi’s advisor: The Federal Court’s decision cut off the road to the government’s demand to sub
» Al-Kazemi’s advisor: A third of the electricity production will recede, and the ration will be avail
» The Minister of Oil confirms work to accelerate gas and clean energy investment plans
» After stopping for more than 12 years, the industry announces the start of the trial operation of th